Our Mission

The Robert M. Berne Cardiovascular Research Center was established to expand basic, translational, and clinical research of cardiovascular diseases. Cardiovascular diseases, including congestive heart failure, hypertension, atherosclerosis, stroke, aneurysms, and vascular auto-immune diseases are the most common cause of death and disability in the United States, and account for approximately 30% of deaths and health care costs annually in this country and developed societies.

The mission of the Robert M. Berne Cardiovascular Research Center is to support interdisciplinary research in basic, translational and clinical cardiovascular sciences, including cardiovascular development, function, pathophysiology, pharmacology, genetics, genomics, and proteomics, and to apply this knowledge to better understand the causes of cardiovascular diseases and to pioneer development of new innovative therapies and approaches to prevent or treat them.

Goals and Objectives

  • To support basic, translational, and clinical research that can be translated into therapies and improve patient care
  • To provide resources that enhance research in cardiovascular related diseases
  • To disseminate knowledge by lectures, seminars and other educational opportunities
  • To support training of pre- and postgraduate students, residents and fellows in the cardiovascular sciences and cardiovascular medicine
  • To help integrate cardiovascular research across labs, departments, and schools at UVA as well as with outside institutions including facilitating collaborative studies
  • To assist CVRC investigators in developing a plan for translating research findings into products or procedures that benefit patients including providing advice on protecting intellectual property, establishing biotech startup companies, and licensing technology to companies


Maddie Jackson, PhD Candidate

Lymphatic endothelial cell cycle control enables lymphatic valve formation The lymphatic vasculature relies on intraluminal valves to maintain unidirectional lymph flow and tissue fluid homeostasis. Disruption to their formation during embryonic development leads to congenital lymphedema, or aberrant pooling of … Read More

Find out more
MR5 Room 3005,

Nick Tsihlis, PhD

Nanoscale Materials to Target Diseases in the Vasculature Cardiovascular disease is the leading cause of mortality globally, with inflammation-inducing atherosclerotic plaque being the main contributing factor. The CANTOS trial showed that decreasing inflammation reduced cardiovascular events without lowering lipids, but … Read More

Find out more
MR5 Room 3005,

Nick Leeper, M.D.

The causal role of cancer in atherosclerosis Cancer and cardiovascular disease are the world’s leading killers.  They share many overlapping risk factors, but emerging data suggest potential causal relationships.  This lecture will describe new evidence suggesting that each disease may … Read More

Find out more
MR5 Room 3005,
MR6 Room 2502,

Esther Lutgens, M.D., PhD

Immune checkpoints in atherosclerosis: a new VISTA I will talk about the role of co-stimulatory and coinhibitory immune checkpoints in atherosclerosis. Not only will I highlight the dangers of immune checkpoint inhibition in cancer treatment on the vasculature, I will … Read More

Find out more
MR5 Room 3005,